RIO Trial Data Shows Delayed HIV Viral Rebound but Raises Resistance Concerns

The Phase 2 RIO trial demonstrates that the antibodies 3BNC117-LS and 10-1074-LS can delay HIV viral rebound after treatment interruption. However, emerging resistance patterns identified in the trial complicate current HIV functional cure strategies. This data introduces new challenges for the development of effective long-term HIV treatments.

Originally published by gnews